Joint Corp Q2 rev $13.3M +5%, narrows loss; cuts FY system-wide sales guidance to $530-550M

JOINT Corp

2025-Q2 EPS reported $0.07 revenue$26,347,860

Q2 revenue $13.3M (+5% YoY); consolidated net income $93K vs loss $3.6M; net loss from continuing ops $990K vs loss $1.7M.
Adjusted EBITDA from continuing ops improved to $88K from loss $380K; consolidated Adj EBITDA up 52% to $3.2M.
Refranchised 37 clinics for $11.2M, acquired NW regional developer territory for $2.8M; franchised now 92% of 967 clinics.
Cuts FY 2025 system-wide sales guidance to $530-550M (from $550-570M); comp sales now low-single digit vs mid-single digit; raises consolidated Adj EBITDA guidance.
Announced restatement of 2024 10-K and Q1 2025 10-Q for non-cash impairment errors; no impact on Adj EBITDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.